Loading
A plain-language account of the KRYSTAL-12 trial, written for patients and carers, explaining how adagrasib compared with docetaxel chemotherapy in previously treated KRAS G12C lung cancer.
Plain language summary of the phase 3 KRYSTAL-12 trial, which randomised previously treated patients with KRAS G12C-mutated non-small-cell lung cancer to the KRAS G12C inhibitor adagrasib or docetaxel. Written by the trial investigators for a non-specialist reader, it restates the design, the progression-free survival result and the side-effect profile of the primary publication.
Europe PMC indexes no abstract for this article, so OnCo carries no figures from it; the trial's own record holds the primary result from the pivotal publication.
Useful for a patient offered adagrasib after chemotherapy or immunotherapy who wants the trial explained without jargon. It adds no new data; the primary KRYSTAL-12 publication and the trial page remain the reference for the numbers.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, Bristol Myers Squibb, Non-small-cell lung cancer.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, Bristol Myers Squibb, Non-small-cell lung cancer.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, Bristol Myers Squibb, Non-small-cell lung cancer.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS, Non-small-cell lung cancer.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, Bristol Myers Squibb.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS, Non-small-cell lung cancer.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS, Non-small-cell lung cancer.
Shares Adagrasib, KRAS, Non-small-cell lung cancer.